Drugs / YTTRIUM Y 90 LABETUZUMAB
YTTRIUM Y 90 LABETUZUMAB
also known as
MN-14 · 90Y hMN-14 · 90Y-Humanized MN-14 Anti-Carcinoembryonic Antigen (CEA) Antibody · 90Y-Labeled Humanized MN-14 · indium In 111 monoclonal antibody MN-14 · Labetuzumab 90y · S9S0Y-HMN-14 · Y90 MOAB MN-14 · +1 more
Monoclonal antibody targets CEACAM5
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00004177 | Aug 1999 → May 2002 | ovarian cancer | Garden State Cancer Center at the Center for Molecular Medicine and Immunology | Completed | No outcome recorded |
| Phase 1/2 | NCT00004085 | May 1998 → May 2002 | breast cancer | Garden State Cancer Center at the Center for Molecular Medicine and Immunology | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YTTRIUM Y 90 LABETUZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108818 ↗ |
| Known as | 90Y hMN-14 | “Patients receive 90Y hMN-14 IV over 30-45 minutes on day 0.” NCT00004177 ↗ |
| Known as | 90Y-Humanized MN-14 Anti-Carcinoembryonic Antigen (CEA) Antibody | “Phase I/II Trial of High-Dose Radioimmunotherapy With a 90Y-Humanized MN-14 Anti-Carcinoembryonic Antigen (CEA) Antibody for the Treatment of Stage IV Breast Cancer” NCT00004085 ↗ |
| Known as | 90Y-Labeled Humanized MN-14 | “Phase I/II Radioimmunotherapy With High-Dose 90Y-Labeled Humanized MN-14 in Advanced Ovarian Cancer Using Autologous Peripheral Blood Stem Cell Rescue (PBSCR) to Control Myelotoxicity” NCT00004177 ↗ |
| Known as | indium In 111 monoclonal antibody MN-14 | “indium In 111 monoclonal antibody MN-14” NCT00004177 ↗ |
| Known as | Labetuzumab 90y | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108818 ↗ |
| Known as | MN-14 | “90Y-Humanized MN-14 Anti-Carcinoembryonic Antigen (CEA) Antibody” NCT00004085 ↗1“indium In 111 monoclonal antibody MN-14” NCT00004177 ↗ |
| Known as | S9S0Y-HMN-14 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108818 ↗ |
| Known as | Y90 MOAB MN-14 | “Patients receive yttrium Y 90 monoclonal antibody MN-14 (Y90 MOAB MN-14) IV for up to 40 minutes on day 0.” NCT00004085 ↗ |
| Known as | yttrium Y 90 monoclonal antibody MN-14 | “yttrium Y 90 monoclonal antibody MN-14” NCT00004177 ↗ |
| Modality | Monoclonal antibody | “indium In 111 monoclonal antibody MN-14” NCT00004177 ↗ |
| Route | Intravenous | “Patients receive yttrium Y 90 monoclonal antibody MN-14 (Y90 MOAB MN-14) IV” NCT00004085 ↗ |
| Target | CEACAM5 | “Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent” CHEMBL2108818 ↗ |